Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib (Vitrakvi).
Overall, a significant amount of patients respond to larotrectinib and the responses appear very durable, Hong says. The hope with LOXO-195, another TRK inhibitor, is to see more of these significant responses and durability in these patients. Like many other small molecule agents, the next steps include determining the mechanisms of resistance and if other drugs can be developed that are less toxic.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
